w2.cytomed.sg (GDTC): Balans kapitallashuviga qarzlar

CytoMed Therapeutics Limited (GDTC) grafik logotipi

CytoMed Therapeutics (GDTC) donor hujayralaridan olingan hamyonbop CAR-T va CAR-NK terapiyalarini ishlab chiqish orqali investorlarni jalb qilmoqda. Balans hisoboti kapitaliga nisbatan joriy leveraj koeffitsiyenti moliyaviy barqarorlikni ko'rsatadi, bunda 0.09 metriki joriy darajani tasdiqlaydi. Biznes samaradorligi yuqori marjali kriogen logistikaga tayanadi, garchi erta bosqichdagi sinovlar va laboratoriya xarajatlari hozirda foydani kengaytirishni cheklayotgan bo'lsa-da.

CytoMed Therapeutics Ltd (GDTC) - Balans qiymatiga qarzlar 21.02.2024dan 27.10.2026gacha

w2.cytomed.sg (GDTC) kompaniyasi koʻrsatkichlari kesimi va tahlili

- narx va narxlar bo'yicha konsensus prognoz:
Narx grafigi CytoMed Therapeutics Limited|GDTC - Investitsiya uylarining umumiy prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi CytoMed Therapeutics Limited|GDTC - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati CytoMed Therapeutics|GDTC - Kompaniyaning xususiy kapitali|Bozor qiymatining balans qiymatiga nisbati w2.cytomed.sg|GDTC - Aktivlarning umumiy qiymati
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning xususiy kapitalga nisbati CytoMed Therapeutics|GDTC - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning kapitalga nisbati CytoMed Therapeutics Limited|GDTC - Kompaniyaning umumiy qarzi|Qarzning balans qiymatiga nisbati CytoMed Therapeutics Limited
Kompaniyaning barcha koʻrsatkichlari tahlili:CytoMed GDTC
w2.cytomed.sg asosiy tovari

Emitentning investitsiya auditini o'tkazish aktivlarni sotib olishdan oldin moliyaviy barqarorlikni puxta baholashni talab qiladi. Ushbu ko'rsatkich jami majburiyatlarning kapitalga nisbati sifatida hisoblanadi va biznesning tashqi moliyalashtirish hamda foiz stavkalariga bog'liqligini o'lchaydi. Kuchli ilmiy xodimlarga ega bo'lgan CytoMed Therapeutics (GDTC) uchun klinik sinovlarni kengaytirishda qarz yuklamasining pastligi kritik ahamiyatga ega. Qarz mablag'larining kitob kapitalizatsiyasiga nisbati menejmentning defolt xavfisiz tadqiqotlarni kengaytirish qobiliyatini aks ettiradi. Qarz mablag'larining kitob kapitalizatsiyasiga nisbatining narx dinamikasi kapital tuzilmasining inflyatsion xarajatlarga moslashuvchanligini tasdiqlaydi.

CytoMed Therapeutics kimlar bilan raqobatlashadi

ONC - Qarzning balans kapitallashuviga nisbati|Qarzning balans qiymatiga nisbati halozyme.com HALO|RVMD: Balans kapitallashuviga qarzlar|AAPG - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar CGON|URGN (UroGen Pharma Corp) - Balans qiymatiga qarzlar|BCAX - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati personalis.com (PSNL)|Erasca (ERAS) - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati Delcath Systems Inc (DCTH)|YmAbs - Balans kapitallashuviga qarzlar|AURA - Qarzning balans qiymatiga nisbati|Candel - Qarzning balans qiymatiga nisbati|ARAY: Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Qarzning sof aktivlarga nisbati|Balans kapitallashuviga qarzlar CTOR (Citius Oncology, Inc)|Balans qiymatiga qarzlar TuHURA|Balans kapitallashuviga qarzlar TARA (Protara Therapeutics)|Qarzning balans qiymatiga nisbati fatetherapeutics.com FATE|WHWK: Qarzning balans qiymatiga nisbati|TCRX - Balans qiymatiga qarzlar|Qarzning balans qiymatiga nisbati Champions Oncology Corp CSBR|XBIT: Qarzning balans kapitaliga nisbati|Qarzning balans kapitallashuviga nisbati CVM|OSTX (ostherapies.com) - Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati RADX|Qarzning balans qiymatiga nisbati Artiva|Adlai Nortye Ltd. - Balans kapitallashuviga qarzlar|Balans qiymatiga qarzlar Veru Corporation (VERU)|TPST - Balans kapitallashuviga qarzlar|XLO - Qarzning balans qiymatiga nisbati|Qarzning balans qiymatiga nisbati Enochian BioSciences (RENB)|Mural Oncology plc (MURA) - Qarzning sof aktivlarga nisbati|KAPA - Qarzning balans qiymatiga nisbati|OnKure Therapeutics (OKUR) - Qarzning balans kapitaliga nisbati|CRIS - Balans kapitallashuviga qarzlar|Qarzning sof aktivlarga nisbati Apollomics Corp|Tharimmune - Balans kapitallashuviga qarzlar|Balans qiymatiga qarzlar ADVB (advanbiomed.com)|Qarzning balans kapitallashuviga nisbati Genprex, Inc|Qarzning sof aktivlarga nisbati Calidi Biotherapeutics Inc. CLDI|Sunshine Biopharma, Inc. - Balans kapitallashuviga qarzlar|XBIO: Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Salarius Pharmaceuticals, Inc. (SLRX)|Purple Biotech Ltd (PPBT) - Qarzlarning balans kapitallashuviga nisbati|Balans kapitallashuviga qarzlar AONC (American Oncology Network Inc)|Balans qiymatiga qarzlar BeiGene Ltd (BGNE)|Qarzning balans qiymatiga nisbati CKPT|Balans kapitallashuviga qarzlar elevationoncology.com ELEV|Qarzning balans qiymatiga nisbati iCAD (ICAD)|Qarzning balans kapitaliga nisbati Ikena Oncology Inc. IKNA|Balans kapitallashuviga qarzlar NTBL (Notable Labs Inc.)|VIRX - Sof aktivlarga qarzlar|MOR (MorphoSys AG) - Balans kapitallashuviga qarzlar|NAYA (nayabiosciences.com) - Qarzning balans qiymatiga nisbati|AAPGV: Qarzning balans kapitallashuviga nisbati